Chemically engineered bispecific antibody directed at the p55 and p75 chains of the human interleukin 2 receptor: specific high-affinity cross-linking of p55/p75 complexes and high blocking effect on IL2-induced T cell proliferation.
François
C
C
INSERM Unité 211, Institut de Biologie, Nantes, France.
Boeffard
F
F
Jacques
Y
Y
D000818:Animals; D000911:Antibodies, Monoclonal / Q000378:metabolism / Q000494:pharmacology*; D002460:Cell Line; D006801:Humans; D007140:Immunoglobulin Fab Fragments / Q000378:metabolism / Q000494:pharmacology; D007074:Immunoglobulin G / Q000378:metabolism / Q000494:pharmacology; D007376:Interleukin-2 / Q000494:pharmacology*; D008213:Lymphocyte Activation / Q000187:drug effects; D046911:Macromolecular Substances; D016853:Muromonab-CD3 / Q000494:pharmacology; D051381:Rats; D015375:Receptors, Interleukin-2 / Q000276:immunology*; D011994:Recombinant Proteins / Q000494:pharmacology; D013601:T-Lymphocytes / Q000187:drug effects / Q000276:immunology*
D000911:Antibodies, Monoclonal; D007140:Immunoglobulin Fab Fragments; D007074:Immunoglobulin G; D007376:Interleukin-2; D046911:Macromolecular Substances; D016853:Muromonab-CD3; D015375:Receptors, Interleukin-2; D011994:Recombinant Proteins